Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2020-002234-32-IT
EUCTR2020-002234-32-ITActive, not recruitingPhase 1

Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19) - CorONa Virus edoxabaN ColchicinE (CONVINCE)

INSEL GRUPPE AG, BERN UNIVERSITY HOSPITAL, DEPARTMENT OF CARDIOLOGY0 sites420 target enrollmentStarted: January 4, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
420
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients >= 18 years old with symptoms compatible with active Coronavirus infection and laboratory confirmed SARS-CoV-2 infection (under RT PCR) who are managed at home or in another out-of-hospital setting.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 300
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 120

Exclusion Criteria

  • •Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including Child-Pugh C cirrhosis with portal hypertension.
  • •Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
  • •Uncontrolled severe hypertension.
  • •Ongoing or planned treatment with parenteral or oral anticoagulants
  • •Unilateral or bilateral above knee lower extremity amputation.
  • •Inability to take oral medication or otherwise unable or unwilling to undergo/perform study-specified procedures
  • •Have received or will receive an experimental drug or used an experimental medical device within 30 days before the planned start of treatment
  • •Pregnancy or breast-feeding or any plan to become pregnant during the study. Women (and men, for Colchicine group only) with child-bearing potential not using adequate birth control method (note: as adequate method of birth control oral contraception is recommended. If oral contraception is not feasible, both partners should use adequate barrier birth control).
  • •Need for dual anti-platelet therapy consisting of aspirin and an oral P2Y12 inhibitor
  • •Inflammatory bowel disease or chronic diarrhea or neuromuscular disease
  • •Creatinine clearance (CrCl) <15 ml/min
  • •Anticipated use of Hydroxychloroquine
  • •Participation in any other clinical trial
  • •Inability to understand the requirements of the study and to provide informed consent

Investigators

Sponsor
INSEL GRUPPE AG, BERN UNIVERSITY HOSPITAL, DEPARTMENT OF CARDIOLOGY

Similar Trials

Active, not recruiting
Phase 1
Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19)
EUCTR2020-002234-32-BEInsel Gruppe AG - Bern University Hospital, Department of Cardiology60
Completed
Phase 4
Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertensioCTEPH (chronic thromboembolic pulmonary hypertension)
JPRN-UMIN000018520Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine60
Completed
Not Applicable
Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver diseasePortal vein thrombosis
JPRN-UMIN000030108Kanazawa University Hospital20
Completed
Not Applicable
A study on efficacy and safety of Edoxaban on high-risk gastrointestinal endoscopic proceduresAll diseases that require high-risk gastrointestinal endoscopic procedures such as endoscopic polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection or endoscopic mucosal ablation
JPRN-UMIN000031523iigata University Graduate School of Medical and Dental Sciences12
Recruiting
Phase 4
It is a study that compare two drugs named Ofloxacin and its Combination with Dexamethasone in the patients of long term ear discharge.
CTRI/2012/07/002784Government Medical College Bhavnagar120